Nitec Pharma Expands Senior Management Team



    BASEL, SWITZERLAND, Oct. 4 /CNW/ - Nitec Pharma AG, today announced a
substantial expansion of its management team. Nitec appointed Dr. Stephan
Witte, as Chief Medical Officer and Head of Global Clinical Development, Dr.
Michael Luttgen as Vice President Marketing & Sales, Dr Hans Rensland as Vice
President Regulatory Affairs, Dr. Rainer Rogasch as Vice President Technical
Operations & Development, Dr. Markus Vogt as Vice President of Quality and
Compliance and James Audibert as Vice President Commercial Optimization.
    "We are excited to be expanding the Nitec team, with all five candidates
having exceptional leadership capabilities and pharmaceutical experience,"
said Anders Harfstrand the CEO of Nitec. "Their track record in successfully
leading companies to the forefront of the industry is outstanding, and we are
confident in their abilities to help taking Nitec forward as a successful
specialty biopharmaceutical company."
    Dr. Stephan Witte, the Chief Medical Officer and Head of Global Clinical
Development, has more than 10 years experience in biomedical research and
clinical development. Before joining Nitec Pharma, he held a variety of
positions with Altana Pharma AG, Quintiles and ICON Clinical Research. His
experience includes design and operative management of global clinical
development programs and clinical studies in the indications asthma and COPD.
Dr. Witte holds a M.S. in Chemistry and completed a PhD thesis at the
University of Konstanz. Subsequently he underwent post-doctoral training at
the La Jolla Institute for Allergy and Immunology in San Diego and completed
post-graduate training in pharmaceutical medicine at the ECPM in Basel.
    Dr. Michael Luttgen, Vice President Marketing & Sales at Nitec, held
senior marketing positions in Mayne Pharma, Cephalon and Baxter Germany during
the last four years. At Baxter, he was Marketing Director for Renal Therapies
in Germany. His career in the pharmaceutical industry began at Merck KGaA, as
sales representative from 1992 to 1995 and the product manager for
corticosteroids from 1995 to 1997. Dr. Luttgen originally studied Biology at
the JWG University, Frankfurt/M, where he was also awarded a PhD in 1993.
    Dr. Hans Rensland, Vice President Regulatory Affairs at Nitec, was for
the last four years the Director of Regulatory Affairs at Biologische
Heilmittel Heel GmbH. Previous to this, he has held senior positions in
Regulatory Affairs in a variety of international acting companies including
Merck KGaA, Knoll AG, and Intersan GmbH. Dr. Rensland completed his PhD in
oncology at the Max Planck Institute for Medical Research in Heidelberg in
1992.
    Dr. Rainer Rogasch will work as Vice President Technical Operations &
Development and was previously General Manager and Technical Director at
Madaus GmbH. Before, Dr. Rogasch was Head of Production and Development at
alphamed Pharbil/PenCef GmbH. Dr. Rogasch also worked in Pharmacy Management
after graduating with a PhD in pharmaceutical technology as Pharmacist from
the Philipps-University Marburg/Lahn, Germany.
    Dr Markus Vogt, Vice President of Quality and Compliance, was formerly
Head of Technical Development at Nitec Pharma. Previous to this, Dr Vogt held
a variety of positions in pharmaceutical development at Merck KGaA. He
received his PhD in pharmaceutical technology from the University of Frankfurt
during this period. He originally studied pharmacy at Johannes
Gutenberg-Universitat, Mainz, and completed the State Exams in pharmacy in
2001.
    James Audibert (based in New Jersey/US), Vice President Commercial
Optimization, has over 30 years of experience in the pharmaceutical industry.
Most of his career was spent with Key Pharmaceuticals and Schering Plough (SP)
where he was involved in US sales and marketing, managed care, global
marketing, and research. From 1995 to 2000, he was responsible for SP's Global
Marketing Cardiovascular Business Unit, and then moved to the Schering Plough
Research Institute, where he was responsible for developing and implementing
new processes for enhancing strategic commercial input into the
drug-development process. He retired from SP in 2004. At Nitec Pharma, Mr.
Audibert's primary responsibility is strategic development and partnering for
the US market, as well as assisting the founders in overall product
development and commercial strategies. He holds a BS in Pharmacy and MS in
Pharmacology from Northeastern University in Boston, MA.

    About Nitec Pharma AG:

    Nitec Pharma is a biopharmaceutical company specialized in the
development and commercialization of optimized medicines for the treatment of
chronic inflammatory diseases and pain. Nitec is headquartered in Reinach,
Switzerland, with a subsidiary in Mannheim, Germany. The Company's most
advanced product is Lodotra(TM), a circadian cytokine modulator (CCMTM) based
on a night time release formulation of prednisone, for the treatment of
rheumatoid arthritis (RA) -addressing in particular the morning stiffness
characteristic of RA. Lodotra(TM) has successfully completed Phase III
clinical trials and will also be developed for other inflammatory diseases.
Nitec was originally founded in 2004 as a spin-out of Merck KGaA. The Company
is financed by Atlas Venture, Global Life Science Ventures and NGN Capital.
For further information about Nitec Pharma please visit
http://www.nitecpharma.com

    This press release contains specific forward-looking statements, e.g.
statements including terms like believe, assume, expect or similar
expressions. Such forward-looking statements are subject to known and unknown
risks, uncertainties and other factors which may result in a substantial
divergence between the actual results, financial situation, development or
performance of the company and those explicitly or implicitly presumed in
these statements. Against the background of these uncertainties readers should
not place undue reliance on forward-looking statements. The company assumes no
responsibility to update forward-looking statements or to adapt them to future
events or developments.





For further information:

For further information: Dr. Anders Harfstrand, CEO, Nitec Pharma AG,
Tel: +41-61-715-20-46, Mobile: +41-79-83493-20, E-mail:
anders.harfstrand@nitecpharma.com; Jochen Mattis, EVP Marketing & Sales/BD,
Nitec Pharma AG, Tel: +41-61-715-20-47, Mobile: +49-151-17-43-33-77, E-mail:
jochen.mattis@nitecpharma.com

Organization Profile

NITEC PHARMA AG

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890